 | | Vol. 6.25 – 19 July, 2021 |
| |
|
|
| Human induced pluripotent stem cell derived cardiomyocytes as well as ex vivo and in vivo models of ischemia-reperfusion injury were used to test the efficacy of ASIC1a inhibitors as pre- and post-conditioning therapeutic agents.
[Circulation] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| AAV9-mediated cardiac specific ADAR2 overexpression attenuated acute myocardial infarction (MI), MI remodeling and doxorubicin-induced cardiotoxicity. In vitro, overexpression of ADAR2 inhibited doxorubicin-induced cardiomyocyte apoptosis, but also induced neonatal rat cardiomyocyte proliferation.
[Molecular Therapy] |
|
|
|
| Both human pluripotent stem cell-derived cardiomyocytes and adult cardiomyocytes could be productively infected by SARS-CoV-2, leading to secretion of the monocyte chemoattractant cytokine CCL2 and subsequent monocyte recruitment.
[Stem Cell Reports] |
|
|
|
| Duchenne muscular dystrophy (DMD)-iPSC-derived cardiomyocytes (iCMs) secreted exosomes containing altered miRNA profiles in comparison to healthy controls. In particular, miR-339-5p was upregulated in DMD-iCMs, DMD exosomes, and in mdx mouse cardiac tissue.
[Human Molecular Genetics] |
|
|
|
| Investigators determined the effect of cell type-specific deletion of protease-activated receptor 1 (PAR1) in cardiac myocytes and cardiac fibroblasts on Coxsackievirus B3-induced myocarditis.
[Scientific Reports] |
| |
|
|
| Researchers described an optimized protocol to differentiate human induced pluripotent stem cells (iPSCs) to a late myogenic stage, allowing them to recapitulate classical Duchenne muscular dystrophy (DMD) phenotypes in isogenic DMD-mutant iPSC lines in vitro.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| After four weeks of exercise training, single nucleus RNA-sequencing revealed that resident muscle stem cells, or satellite cells, were activated with acute exercise, but demonstrated limited lineage progression while contributing to muscle adaptation.
[iScience] |
|
|
|
| Estradiol (E2) and the clinically used selective estrogen receptor modulator toremifene increased miR-486 in undifferentiated and differentiated myoblast cell line C2C12 and E2-inducible expression correlated with direct binding of estrogen receptor alpha to the regulatory region of miR-486 gene.
[Endocrinology] |
| |
|
|
| Scientists investigated the effects of nicotine on the initiation of vascular smooth muscle cell (VSMC) calcification. In vitro, nicotine-induced human primary VSMC calcification, increased osteogenic gene expression, and extracellular vesicle secretion.
[Cardiovascular Research] |
|
|
|
| The authors investigated the role of prorelaxant cAMP-protein kinase A signaling in diacylglycerol kinase-mediated regulation of airway smooth muscle contraction.
[Journal of Cellular Physiology] |
|
|
|
| Researchers investigated the heterogeneity of vascular cell populations under disturbed blood flow (d-flow). A d-flow-induced Spp1hi vascular smooth muscle cell subpopulation appeared to be endowed with osteoblast differentiation, suggesting a role in arterial stiffness.
[Cell Death Discovery] |
|
|
|
| The authors explored the regulatory relationship between airway smooth muscle genes to uncover the putative mechanism underlying asthma in humans.
[Scientific Reports] |
|
|
|
|
Investigators examined the role of Sirtuin1 in angiotensin II-induced overexpression of Giα proteins and hyperproliferation of aortic vascular smooth muscle cells.
[American Journal of Physiology-Heart and Circulatory Physiology] |
|  | |
|
|
| Scientists discuss how defects in muscle proteins give rise to muscle dysfunction, and ultimately to disease, with a focus on pathologies that are most common, best understood and that provide the most insight into muscle biology.
[Nature Reviews Molecular Cell Biology] |
|
|
|
| The authors present the generation, development, and application of current cellular, animal and potential for bio-printed models, in the study of the pathophysiological mechanisms underlying dystrophin-linked cardiomyopathy in the direction of personalized medicine.
[Cardiovascular Research] |
|
|
|
|
| Imbria Pharmaceuticals announced that the Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the IMPROVE-HCM study, a Phase II study of the safety, tolerability, and efficacy of IMB-101 in patients with non-obstructive hypertrophic cardiomyopathy.
[Imbria Pharmaceuticals] |
|
|
|
|
| August 7 – 12, 2022
Andover, New Hampshire, United States |
|
|
|
|
|
| | Pompeu Fabra University – Barcelona, Spain |
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| | Stanford University – Palo Alto, California, United States |
|
|
|
| | Hannover Medical School – Hannover, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
